Acor­da los­es its last shot at pro­tect­ing its cash cow fran­chise drug. It’s up to In­bri­ja now

Acor­da has lost its last-ditch at­tempt to re­tain con­trol of the cash cow it bad­ly need­ed to sus­tain the com­pa­ny. The Supreme Court has re­fused to hear its ar­gu­ment against a low­er court rul­ing that opened the gate to knock­offs of its mul­ti­ple scle­ro­sis drug Ampyra.

Acor­da has been gear­ing for this day for more than 2 years, get­ting a de­layed ap­proval of In­bri­ja — an in­hala­tion pow­der of lev­odopa — late last year, which com­pa­ny ex­ecs hope will re­place Ampyra as the main rev­enue stream dwin­dles. But in Q2 they gained on­ly $3 mil­lion in sales from the new drug — well be­low con­sen­sus — while con­tin­u­ing to do much bet­ter than ex­pect­ed on the fad­ing fran­chise.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.